Prophylaxis Guided by CMV-Specific T-Cell Immunity in Lung Transplant Recipients: Prospective Interventional Study (ISHLT 2026) - Feb 2, 2026 - Abstract #6 / Pub #202; Pres time: Apr 24, 2026; 04:01 PM - 04:09 PM; Location: Room 801 A+B; "All participants received valganciclovir or letermovir prophylaxis post-transplant and serial monitoring of CMV-specific CD4⁺ and CD8⁺ T-cell responses (CMV inSIGHT™, Eurofins Viracor) at months 0, 3, 4, 5, 6, and 9 post-transplant. As a secondary endpoint, we collect the proportion of CMV-specific CD4 interferon gamma cells at 0, 3, 4, 5, 6, and 9 months post-transplant; CMV disease incidence and severity; graft function, including rejection incidence and severity; and mortality. Of note, we collect all CMV DNAemia, at any level and ≥1000 IU/mL."
Clinical • Late-breaking abstract • Cytomegalovirus Infection • Infectious Disease • Transplantation • CD4 • CD8 • IFNG
|
|
K. N. Magee 1; J. Fernandez-Castillo 2; S. Kleiboeker 3; S. Al-Bayati 4; J. Solera 2; R. Mujica-Palacios 2; J. Salgado 2; M. Gil-Barturen 5; M. Pipkin 5; A. Pelaez 2; Y. Natori 2
|